2469 |
Unrestricted Adoption in Real World Patients Is Possible. |
Patrick W. Serruys |
Apr. 20. 15 |
2468 |
The Sapien 3 Valve: Next Generation Balloon Expandable Valve Designed to Minimize Paravalvular Regurgitation |
Susheel Kodali |
Apr. 20. 15 |
2467 |
Corevalve Evolute R: The New Very Promising Generation of Corevalve |
Bernard R. Chevalier |
Apr. 20. 15 |
2466 |
FORTIS Transcatheter Mitral Valve for Treatment of a Patient with Severe Mitral Regurgitation |
Jian (James) Ye |
Apr. 20. 15 |
2465 |
Experience in Complex Lesions & Acute MI |
Corrado Tamburino |
Apr. 20. 15 |
2464 |
Clinical Data: What Do We Learn from Absorb II Trial? |
Bernard R. Chevalier |
Apr. 20. 15 |
2463 |
The Lotus Valve: Minimization of Paravalvular Leak with a Repositionable Next Generation TAVR Device |
Ted Feldman |
Apr. 20. 15 |
2462 |
Syntax 2 case : Multivessel Coronary Disease but Single Wessel Intervention |
Pawel E. Buszman |
Apr. 20. 15 |
2461 |
New Indications for CTO Recanalization |
Barry D. Rutherford |
Apr. 20. 15 |
2460 |
Should We Open Every CTO?: DECISION CTO |
Seung-Whan Lee |
Apr. 20. 15 |